Leucine-Rich Alpha-2-Glycoprotein: A Novel Predictor of Diastolic Dysfunction

Abstract

Leucine-rich α2-glycoprotein (LRG1) mediates cardiac fibrocyte activation. It is upregulated in inflammatory conditions, atherosclerosis, and fibrosis. Diastolic dysfunction (DD) is due to myocardial fibrosis. This cross-sectional study examined the relationship between LRG1 and DD. Patients with symptoms of chronic coronary ischemia were recruited. Patients with symptoms of overt heart failure, ejection fraction (EF) p < 0.001) higher in the DD group (M = 14) compared to the No-DD group (M = 8) by Mann–Whitney U test. There were higher SYNTAX scores in the DD group (M = 24.5) compared with No-DD (M = 7). LRG1 had significant predictability of DD (OR = 1.32 (95% CI: 1.14–1.53)). The ROC showed an AUC = 0.89 (95% CI: 0.82–0.95). LRG1 had a 78% sensitivity (95% CI: 65.3–87.7) and 72.3% specificity (95% CI: 57.4–84.4) for predicting DD at a cut-off value of “9”. In conclusion, we identified LRG1 as a novel independent predictor of DD. Further studies are warranted to validate the utility of LRG1 in predicting DD.

Keywords

• leucine-rich alpha-2-glycoprotein 1 (LRG1)
• diastolic dysfunction
• biomarker
• heart failure with preserved ejection fraction (HFpEF)
• cross-sectional study